Cell Source · raw details

Cell Therapy Treatments Based on Immune Tolerance · Bnei Brak · Founded 2011

active Public ← back to profile

Highlights

1 patent

About

Cell Therapy Treatments Based on Immune Tolerance

Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company's patented Veto Cell technology enables safe and selective tuning of immune responses. Veto Cells are white blood cells taken from either the patient or a healthy third-party donor. They are then processed using a proprietary mix of off-the-shelf, FDA-approved cytokines that change their characteristics and activate their inherent attacker-blocking capability. Once reintroduced into the body intravenously, they can perform a number of important functions. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating blood cancers such as lymphoma and nonmalignant congenital diseases such as sickle cell anemia.

Identity

NameCell Source
Slugcell-source
Type / kindstartup
Crunchbase IDcell-source
Source _idagxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6Jqd8IDA

Status

Statusactive
Status reasonPublic on OTC on May, 2014;
Last update2026-05-17

Location

HQ country codeIL
HQ region/districtCenter District
HQ cityBnei Brak
HQ addressKinneret St 5, Bnei Brak, Israel

Web & social

Websitehttps://cell-source.com

Classifications

Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiomaterials & Tissue Engineering
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business models
B2B
Tags
immunologybiological-therapyregenerative-medicinecell-therapycancerpharma-companies

Funding

Total raised$21.5M
Current stagePublic
Market cap$22.5M

Raw source document

Show full JSON (0 KB)
{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}